Postdoctoral Research Fellow University of Wisconsin-Madison
Introduction: AIS may develop in patients with COVID-19; we aim to study the association between COVID-19 and risks of developing AIS.
Methods: We analyzed NIS 2020, the largest publicly inpatient database to produce U.S. regional and national estimates of inpatient utilization, access, quality, and outcomes.
Results: A total of 674,354 AIS patients and 1,678,995 COVID-19 patients with Primary,Secondary diagnosis in the NIS 2020. 7560(0.75%) patients developed AIS among 1058815 patients diagnosed with COVID-19 as primary diagnosis, while 505884(1.64%) developed AIS among 30,676,832 patients without COVID-19. COVID-19 patients who developed AIS had a greater mean age than those who did not(68.74 vs.64,32; p< 0.0001). Proportion of white patients was lower(44.91% vs,50,09%; p< 0.0001), black patients was higher(22.88% vs,17.89%; p< 0.0001) and Hispanic patients was no difference(18.19% vs,20.06%; p=0.06) between COVID-19 patients developed AIS and patients without stroke. Proportions of patients with Charlson comorbidity index(≥3: 68.32 vs,27.54%;p < 0.0001), hypertension(74.47% vs, 67.11%; p< 0.0001), diabetes(40.94% vs, 34.18%; p< 0.0001), hyperlipidemia(41.79 vs, 39.02%; p=0.02), Atrial fibrillation(27.58% vs,14.99%; p< 0.0001), coagulopathy(26.32% vs, 10.86%; p< 0.0001) and heart failure(23.54% vs, 15.62%; p< 0.0001) were significantly higher between COVID-19 patients developed AIS and patients without stroke. Proportions of patients developed cerebral edema(8.53% vs, 0.13%;p < 0.0001), intracerebral Hg(6.15% vs, 0.1%;p < 0.0001), subarachnoid hg(1.65% vs, 0%;p < 0.0001), kidney injury(49.21% vs,24.94%;p < 0.0001), liver failure (3.21% vs, 0.85%;p < 0.0001), urinary tract infection(12.57% vs, 7.9%;p < 0.0001), septic shock (23.88% vs, 6.1%;p < 0.0001), Deep Venous thrombosis(8.13% vs, 2.07%;p < 0.0001), pulmonary embolism (5.75% vs, 2.8%;p < 0.0001) and Acute myocardial infarction(11.97% vs, 3.34%;p < 0.0001).There was no difference in proportions of pneumonia, systems inflammatory response syndrome, and respiratory failure. Proportions of hospital mortality (37.39% vs. 10.89%; p< 0.0001) were higher, home discharge(13.69% vs., 55.2%; p< 0.0001) were lower between COVID-19 patients developed AIS and patients without stroke.
Conclusion : Probability of developing AIS after COVID-19 is high in presence of comorbidities.
